Related Experiment Video
Updated: Dec 27, 2025
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Biomimetic nanoparticle technology for cardiovascular disease detection and treatment
Joon Ho Park1, Diana Dehaini1, Jiarong Zhou1
1Department of NanoEngineering, Chemical Engineering Program, and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Insights
Nanotechnology offers new ways to diagnose and treat cardiovascular disease (CVD). Nanoscale delivery systems can target specific sites, improving drug effectiveness for heart and blood vessel conditions.
Area of Science:
- Biomedical Engineering
- Materials Science
- Cardiology
Background:
- Cardiovascular disease (CVD) is a leading cause of death globally, affecting nearly one in three individuals.
- Current CVD treatments have limitations, necessitating innovative therapeutic and diagnostic approaches.
- Nanotechnology presents a promising frontier for advancing cardiovascular care.
Purpose of the Study:
- To review the applications of nanotechnology in cardiovascular disease diagnostics and treatments.
- To explore the potential of nanoscale delivery systems for improved CVD management.
- To discuss novel biomimetic platforms with enhanced functionalities for cardiovascular applications.
Main Methods:
- Literature review of current research on nanotechnology in CVD.
- Analysis of nanoparticle-based delivery systems for targeted drug delivery.
- Discussion of biomimetic platforms for advanced CVD management.
Main Results:
- Nanoscale delivery systems offer advantages like targeted delivery to diseased sites.
- Nanoparticles can enhance drug bioavailability and carry diverse functional payloads.
- Emerging biomimetic platforms show potential for improved CVD diagnostics and therapeutics.
Conclusions:
- Nanotechnology holds significant promise for revolutionizing cardiovascular disease diagnosis and treatment.
- Targeted nanoparticle delivery systems can overcome limitations of current CVD therapies.
- Further development of functional biomimetic platforms is crucial for future CVD management strategies.
Abstract:
Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.
